株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

キーオピニオンリーダー (KOL) の見解:ウステキヌマブの治験データ

KOL Perceptions of Ustekinumab Data Presented at ACR 2017

発行 GlobalData 商品コード 721707
出版日 ページ情報 英文 30 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.52円で換算しております。
Back to Top
キーオピニオンリーダー (KOL) の見解:ウステキヌマブの治験データ KOL Perceptions of Ustekinumab Data Presented at ACR 2017
出版日: 2018年06月26日 ページ情報: 英文 30 Pages
概要

当レポートでは、米国リウマチ学会主催の「ARC 2017」で発表された、ウステキヌマブの現在までの治験成果や、市場での受容度、リウマチ薬としての今後の利用・普及見通しなどについて、業界のキーオピニオンリーダー (KOL) に対する聞き取り調査を実施し、その結果を取りまとめてお届けいたします。

目次

  • エグゼクティブ・サマリー
  • 背景事情
  • 調査パネルの構成
  • 調査結果とその意義

付録

目次
Product Code: GDHC032SP

This KOL Insight briefing focuses on perceptions of Ustekinumab Data Presented at ACR 2017.

The briefing includes analysis of KOL opinion on the following topic areas -

  • Perception of ustekinumab's Phase II efficacy data in SLE
  • Views on ustekinumab demonstrating significant efficacy at Week 24 in SLE
  • Ustekinumab's Phase II CLASI data in SLE
  • Ustekinumab's Phase II safety data in SLE
  • Impact of ustekinumab data in other indications on opinion of ustekinumab in SLE
  • Endpoints used in the Phase II ustekinumab trial in SLE
  • Anticipated future use of ustekinumab in SLE
  • Ideal additional endpoints or data for future ustekinumab trials in lupus

Key Highlights

  • Most KOLs had a positive opinion of ustekinumab's efficacy in SLE and highlighted that it appears to have a better response rate vs. belimumab
  • KOLs were broadly impressed with ustekinumab's CLASI data, and expect it to encourage ustekinumab uptake in lupus skin manifestations
  • Most KOLs had a positive view of ustekinumab's safety, but concerns were raised regarding the small patient population in the Phase II trial.

Scope

  • The insight briefing is based on Sociable Pharma's analysis of primary research with our lupus key opinion leaders (KOLs)
  • In total, we conducted interviews with 14 KOLs: Seven Europe-based & seven US-based
  • Interviews performed in December 2017.

Reasons to buy

  • Combines Qualitative & semi-quantitative insight from key opinion leaders on "Ustekinumab Data Presented at ACR 2017"
  • Includes insight & recommendations from our disease-specific healthcare analysts
  • Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of Lupus
  • Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

Table of Contents

  • Executive Summary
  • Background
  • Research Panel Composition
  • Results & Implications

Appendix

Back to Top